in the policy) by third parties. The policy also enables the commission to confirm certain nonpublic information that has not been confirmed by third parties. Under the new policy, the Commission will confirm the fact that it is investigating a transaction after the transaction itself has been made public and regardless of whether the fact of the investigation has been made public by third parties.

The Commission long has followed a policy of declining to confirm the existence of its investigations until it issues or authorizes filing of a complaint, or until the matter is closed.[1] This policy is based on the premise that public disclosure of pending investigations and identification of targets can interfere with the conduct and successful resolution of such matters.[2] The Commission concluded in the 1977 Policy Statement that ''disclosure of the identities of businesses under investigation would cause those businesses severe economic injury even before the Commission determines whether there is reason to believe the law has been violated.''

I have been informed that the business community will have no objection to having the Commission confirm the fact that it is investigating a transaction even if the parties have not confirmed the fact of the investigation. I do not know the basis for this information. Assuming the information is correct, I support the new policy in its entity because the policy presumably would not result in the harm the Commission identified in 1977.[3] Nevertheless, I would have preferred to seek comment on this aspect of the new policy before adopting it. Good reasons support the Commission's long standing policy not to confirm or deny the existence of a nonpublic investigation, and the Commission has been able to live with that policy for many years. It seems appropriate and not unduly burdensome for the Commission to seek public comment on this aspect of the proposal for thirty days before adopting it. To the extent that the Commission has chosen not to seek public comment, I dissent.

[FR Doc. 97–9820 Filed 4–15–97; 8:45 am]

BILLING CODE 6750–01–M

[1] In 1977, the Commission reaffirmed its then-current policy of maintaining the confidentiality of most nonpublic investigations. *See* FTC Policy statement, 42 Fed. Reg. 64,135 (Dec. 22, 1977) (''1977 Policy Statement''). This Policy Statement sets forth exceptions for industrywide investigations and investigations involving ''significant risk of economic harm or risk to public health or safety.'' In addition, certain investigations may become public by operation of law or the Commission's Rules, for example, on filing of a petition to quash compulsory process, 16 C.F.R. § 4.9(b)(4), on filing of an application for clearance, 16 C.F.R. § 4.9(10(ii), or on publication in the **Federal Register** of a notice of early termination under the Clayton Act, 15 U.S.C. § 18a(b)(2).

[2] *Id. See also* Exemption 7A to the mandatory public disclosure requirements of the Freedom of Information Act, 5 U.S.C. § 552(b)(7)(A); and Exemption 7A to the open meeting requirements of the Government in the Sunshine Act, 5 U.S.C. § 552b(c)(7)(A).

[3] See note 1.

GENERAL SERVICES ADMINISTRATION

Federal Acquisition Policy Division, FAR Secretariat; Cancellation of Standard Forms

AGENCY: General Services Administration.

ACTION: Notice.

SUMMARY: Since 48 CFR 52.215–41 and 42 give agencies more flexible procedures in requesting exceptions for submitting certified cost and pricing data, the following Standard Forms are canceled:

SF 1412, Request For Exemption From Submission Of Certified Cost Or Pricing Data.

SF 1412A, Request For Exemption From Submission Of Certified Cost Or Pricing Data—Continuation.

DATES: Effective April 16, 1997.

FOR FURTHER INFORMATION CONTACT: Ms. Barbara Williams, General Services Administration, (202) 501–0581.

Dated: March 19, 1997.

Barbara M. Williams,

Deputy Standard and Optional Forms Management Officer.

[FR Doc. 97–9754 Filed 4–15–97; 8:45 am]

BILLING CODE 6820–34–M

GENERAL SERVICES ADMINISTRATION

Interagency Committee for Medical Records (ICMR); Revision of SF 93, Medical Record—Report of Medical History

AGENCY: General Services Administration.

ACTION: Notice.

SUMMARY: The General Services Administration/ICMR is revising the SF 93, Medical Record—Report of Medical History to update the information collected on the patient. You can obtain the updated form in three ways:

From the ''U.S. Government Management Policy CD–ROM'';

On the internet. Address: http://www.gsa.gov/forms, or;

Through the Federal Supply Service using National Stock Number 7540–00–181–8368 (revision 6–96).

FOR FURTHER INFORMATION CONTACT: Ms. Barbara Williams, General Services Administration, (202) 501–0581.

DATES: Effective April 16, 1997.

Dated: March 20, 1997.

Barbara M. Williams,

Deputy Standard and Optional Forms Management Officer.

[FR Doc. 97–9753 Filed 4–15–97; 8:45 am]

BILLING CODE 6820–34–M

GENERAL SERVICES ADMINISTRATION

Real Estate Management; Cancellation of a Standard Form

AGENCY: Public Building Service, General Services Administration.

ACTION: Notice.

SUMMARY: This notice announces the General Services Administration's intent to cancel the following Standard form because of low user demand: SF 2B, U.S. Government Lease for Real Property (Short Form).

This form was replaced with GSA Form 3626, U.S. Government Lease for Real Property (Short Form). You can get copies of this form from the contact person mentioned below or from the following internet address: http://www.gsa/gov/pbs/pe/standcla/standcla.htm.

FOR FURTHER INFORMATION CONTACT: Mr. Gary Roberts, Real Estate Management Division, Office of Property Acquisition and Realty Services, (202) 501–0407.

DATES: Effective April 16, 1997.

Dated: March 7, 1997.

Theodore D. Freed,

Standard and Optional Forms Management Officer.

[FR Doc. 97–9755 Filed 4–15–97; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Manoj Misra, Ph.D., Dartmouth College: Based upon the Office of Research Integrity's (ORI) review of a report forwarded to ORI by Dartmouth

College, Dr. Misra's admission of certain facts in that report, and ORI's own analysis, ORI found that Dr. Misra, a former postdoctoral research associate, Department of Chemistry, Dartmouth College, engaged in scientific misconduct by intentionally altering laboratory notebook data entries for research supported by a grant from the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH).

Specifically, Dr. Misra altered laboratory notebook data entries in two instances in an effort to conceal prior manipulations of that data without disclosure or explanation to the principal investigator or anyone else. The experiment at issue involved an assay of the chemical activity of a carcinogen, and Dr. Misra's change in the readings of the ''control'' experiment, in which no carcinogen was present, changed the results.

Dr. Misra has accepted the ORI finding and has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning April 7, 1997:

(1) To exclude himself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which Dr. Misra's participation is proposed or which uses him in any capacity on PHS supported research must concurrently submit a plan for supervision of his duties. The supervisory plan must be designed to ensure the scientific integrity of Dr. Misra's research contribution. The institution must submit a copy of the supervisory plan to ORI.

No scientific publications were required to be corrected as part of this Agreement.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–9733 Filed 4–15–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee (NVAC), Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage, Subcommittee on Future Vaccines, and the Advisory Commission on Childhood Vaccines (ACCV) Subcommittee on Vaccine Safety: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and dates: 8:45 a.m.–12:15 p.m., May 1, 1997. 8:30 a.m.–1:15 p.m., May 2, 1997.

Place: Hubert H. Humphrey Building, Room 703A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Purpose: This committee advises and makes recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.

Matters to be discussed: Agenda items will include a National Vaccine Program Office (NVPO) update; a discussion on review of the Department of Health and Human Services' Adult Immunization Plan; a discussion on the survey on practices of non-traditional providers; a report of meeting on simian-virus-40—next steps; AIDS vaccine, the progress in vaccine development and organizational approach; the national vaccine plan focusing on priorities; tuberculosis vaccines, barriers and opportunites; the National Institutes of Health (NIH) will discuss their program on tuberculosis and vaccine options; discussion from the Advisory Council on the Elimination of Tuberculosis; improving immunization coverage report from the Sabin Foundation; report from the Subcommittee on Immunization Coverage; report from the Subcommittee on Future Vaccines; report from the Subcommittee on Vaccine Safety; and status of the Work Group on philosophical exemptions.

Agenda items are subject to change as priorities dictate.

Name: Subcommittee on Vaccine Safety and the Advisory Commission on Childhood Vaccines, Subcommittee on Vaccine Safety.

Time and date: 1:15 p.m.–5 p.m., May 1, 1997.

Place: Hubert H. Humphrey Building, Room 425A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This joint NVAC/ACCV subcommittee will review issues relevant to vaccine safety and adverse reactions to vaccines.

Matters to be discussed: This subcommittee will discuss the update on the Public Health Service vaccine safety activities; vaccine safety surveillance overview; vaccine safety funding; and agenda items for next meeting.

Name: Subcommittee on Immunization Coverage.

Time and date: 1:15 p.m.–5 p.m., May 1, 1997.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters to be discussed: This subcommittee will discuss the review of recommendations from the document ''Strategies to Sustain Immunization Coverage'; and a discussion and finalization of the recommendations.

Name: Subcommittee on Future Vaccines.

Time and date: 1:15 p.m.–5 p.m., May 1, 1997.

Place: Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Future Vaccines will develop policy options and guide national activities which will lead to accelerated development, licensure, and best use of new vaccines in the simplest possible immunization schedules.

Matters to be discussed: This subcommittee will discuss an update on vaccine procurement strategies and case studies in vaccine development.

Contact person for more information: Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639–7250.

Dated: April 11, 1997.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–9902 Filed 4–15–97; 8:45 am]

BILLING CODE 4163–18–P